DELAFLOXACIN MEGLUMINE
Manufacturer: Melinta Therapeutics, LLC
Score: 144.0
Baxdela is a fluoroquinolone antibacterial drug used for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria. The drug has shown efficacy in clinical trials, but it also carries important safety information, including warnings about tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. The recommended dosage regimen is 300 mg by intravenous infusion every 12 hours or 450 mg orally every 12 hours, with duration of treatment ranging from 5 to 14 days for ABSSSI and 5 to 10 days for CABP. Special population considerations include use in pregnancy, pediatric use, and geriatric use, with warnings about potential risks and limited data available.
Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions, including tendinitis, tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis
Dosage adjustment is required for patients with severe renal impairment (eGFR 15-29 mL/min/1.73m^2)
300 mg by intravenous infusion every 12 hours or 450 mg orally every 12 hours
Not recommended for use in patients under 18 years of age
300 mg by intravenous infusion every 12 hours or 450 mg orally every 12 hours
Not recommended for use in patients under 18 years of age
MOXIFLOXACIN
A-S Medication Solutions
MOXIFLOXACIN HYDROCHLORIDE TABLETS, 400 MG
MSN LABORATORIES PRIVATE LIMITED
MOXIFLOXACIN HYDROCHLORIDE TABLETS, 400 MG
PD-Rx Pharmaceuticals, Inc.